Brefeldin A (Synonyms: BFA; Cyanein; Decumbin)

Name: Brefeldin A
Brand: MedChemExpress
SKU: HY-16592
Rating: 5.0 (153 reviews)

Cat. No.: HY-16592 Purity: 99.82%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Brefeldin A (BFA) is a lactone antibiotic and a specific inhibitor of protein trafficking. Brefeldin A blocks the transport of secreted and membrane proteins from endoplasmic reticulum to Golgi apparatus. Brefeldin A is also an autophagy and mitophagy inhibitor. Brefeldin A inhibits HSV-1 and has anti-cancer activity.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

CAS No. : 20350-15-6

사이즈	재고	수량

무료 샘플 (0.1 - 0.2 mg)	지금 신청하기
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	해외재고보유	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	해외재고보유	Estimated Time of Arrival: December 31
Solid
5 mg	해외재고보유	Estimated Time of Arrival: December 31
10 mg	해외재고보유	Estimated Time of Arrival: December 31
25 mg	해외재고보유	Estimated Time of Arrival: December 31
50 mg	해외재고보유	Estimated Time of Arrival: December 31
100 mg	해외재고보유	Estimated Time of Arrival: December 31
200 mg	견적 받기
500 mg	견적 받기

or 대량구매 문의

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 153 publication(s) in Google Scholar

Other Forms of Brefeldin A:

Brefeldin A (Standard) In-stock

153 Publications Citing Use of MCE Brefeldin A

Cell Proliferation/Viability Assay

RT-PCR

: Brefeldin A purchased from MedChemExpress. Usage Cited in: Nat Metab. 2024 Aug;6(8):1601-1615. [Abstract]; Brefeldin A (0.5 μg/mL; 12 h) significantly induces the expression of Xbp1s and reduces the expression of Gcg in GLUTag and GLARE cells.

: Brefeldin A purchased from MedChemExpress. Usage Cited in: Autophagy. 2024 Oct;20(10):2221-2237.; Brefeldin A (100 nM; 6 h) promotes upregulation of PLK2 protein in MDA-MB-231 cells.

: Brefeldin A purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Sep 19:e2403442. [Abstract]; Brefeldin A significantly promotes CD36 ubiquitination in Caco2 cells.

: Brefeldin A purchased from MedChemExpress. Usage Cited in: Cell Rep. 2023 Mar 26;42(4):112306. [Abstract]; Brefeldin A (BFA) slightly reduces the ubiquitination of STING in HEK293T cells (transfection with Myc-STING, FLAG-TRIM10, and HA-Ub for 24 h).

: Brefeldin A purchased from MedChemExpress. Usage Cited in: Theranostics. 2021 Jun 1;11(15):7491-7506. [Abstract]; Brefeldin A (BFA, 0.01-50 μM; 24 h) shows less cytotoxicity in SW480 human colon cancer cell line (IC₅₀=4.652 µM) than that in DLD-1 cells (IC₅₀=0.167 µM).

: Brefeldin A purchased from MedChemExpress. Usage Cited in: Theranostics. 2021 Jun 1;11(15):7491-7506. [Abstract]; Brefeldin A (BFA; 2.5-10 mg/kg; i.p., every other day for two doses) suppresses cGAS expression in DSS-induced acute colitis mice.

: Brefeldin A purchased from MedChemExpress. Usage Cited in: FASEB J. 2019 Apr;33(4):5520-5534. [Abstract]; Apoptotic effects induced by BFA are examined in CRC cells.

: Brefeldin A purchased from MedChemExpress. Usage Cited in: FASEB J. 2019 Apr;33(4):5520-5534. [Abstract]; The interaction of Beclin 1 with Bcl-2 or ATG14L after BFA treatment is determined by coimmunoprecipitation assay.

: Brefeldin A purchased from MedChemExpress. Usage Cited in: FASEB J. 2019 Apr;33(4):5520-5534. [Abstract]; CRC cells are treated with vehicle, BFA (100 nM), 3-MA (10 mM), or in combination for 24 h. Immunoblot analysis is used to detect LC3 turnover.

: Brefeldin A purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2019 Apr;23(4):2399-2409. [Abstract]; MHCC-97H cells are treated with BFA (2.5 μg/mL) for 0, 0.5, 1, 2, 6, and 12 h. The expression of GP73 and intracellular MMP-2 is measured using immunoblotting.

: Brefeldin A purchased from MedChemExpress. Usage Cited in: J Radiat Res. 2017 Jul 1;58(4):474-486. [Abstract]; Images showing the morphology of axons after 2.0 mT of 50 Hz MF exposure for 3 days, 1 h per day. Histograms showing the average axon length per neuron, the average axon branch length per neuron and the average number of branches per axon in the sham and exposure groups. Neurons were treated with 1.0 µg/mL brefeldin A at DIV2 as a positive control.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HSV Isoform Specific Products:

View All Isoforms

HSV-1 HSV-2 HSV

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

Biological Activity
Protocol
순도&문서
References
고객리뷰

제품 설명

Brefeldin A (BFA) is a lactone antibiotic and a specific inhibitor of protein trafficking. Brefeldin A blocks the transport of secreted and membrane proteins from endoplasmic reticulum to Golgi apparatus^[1]^[2]. Brefeldin A is also an autophagy and mitophagy inhibitor^[3]. Brefeldin A inhibits HSV-1 and has anti-cancer activity^[5].

IC₅₀ & Target^[5]^[6]

HSV-1

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	0.039 3 Compound: BFA	Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
Bel-7402	IC₅₀	0.024 3 Compound: BFA; 1	Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 29524728]
A-375	IC₅₀	0.039 3 Compound: BFA	Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
A549	GI₅₀	0.04 3 Compound: 1	Antiproliferative activity against human A549 cell line Antiproliferative activity against human A549 cell line	[PMID: 16789745]
Bel-7402	IC₅₀	0.07 3 Compound: BFA	Antiproliferative activity against human Bel-7402 cells by MTT assay Antiproliferative activity against human Bel-7402 cells by MTT assay	[PMID: 36089748]
A549	GI₅₀	0.04 3 Compound: 1	Antiproliferative activity against human A549 cell line Antiproliferative activity against human A549 cell line	[PMID: 16789745]
A549	IC₅₀	0.056 3 Compound: BFA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
Bel-7402	IC₅₀	0.17 3 Compound: 1; BFA	Antiproliferative activity against human Bel-7402 cells measured after 72 hrs by MTT assay Antiproliferative activity against human Bel-7402 cells measured after 72 hrs by MTT assay	[PMID: 35849940]
A549	IC₅₀	0.056 3 Compound: BFA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
Bel-7402	IC₅₀	0.024 3 Compound: BFA; 1	Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 29524728]
Bel7402/5-FU	IC₅₀	0.82 3 Compound: BFA; 1	Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by MTT assay	[PMID: 29524728]
Bel-7402	IC₅₀	0.07 3 Compound: BFA	Antiproliferative activity against human Bel-7402 cells by MTT assay Antiproliferative activity against human Bel-7402 cells by MTT assay	[PMID: 36089748]
ECa-109 cell line	IC₅₀	0.14 3 Compound: 1; BFA	Antiproliferative activity against human Eca-109 cells measured after 72 hrs by MTT assay Antiproliferative activity against human Eca-109 cells measured after 72 hrs by MTT assay	[PMID: 35849940]
Bel-7402	IC₅₀	0.024 3 Compound: BFA; 1	Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 29524728]
Bel-7402	IC₅₀	0.17 3 Compound: 1; BFA	Antiproliferative activity against human Bel-7402 cells measured after 72 hrs by MTT assay Antiproliferative activity against human Bel-7402 cells measured after 72 hrs by MTT assay	[PMID: 35849940]
HeLa	IC₅₀	0.07 3 Compound: 1; BFA	Antiproliferative activity against human HeLa cells measured after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells measured after 72 hrs by MTT assay	[PMID: 35849940]
Bel-7402	IC₅₀	0.07 3 Compound: BFA	Antiproliferative activity against human Bel-7402 cells by MTT assay Antiproliferative activity against human Bel-7402 cells by MTT assay	[PMID: 36089748]
Bel7402/5-FU	IC₅₀	0.82 3 Compound: BFA; 1	Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by MTT assay	[PMID: 29524728]
HeLa	EC₅₀	5 3 Compound: Brefeldin A	Inhibition of Escherichia coli Stx1 in human HeLa cells assessed as stimulation of protein synthesis by measuring increase in [14C]-leucine incorporation incubated with cells for 1 hr prior to Stx1 addition and further incubated for 1 to 24 hrs and subseq Inhibition of Escherichia coli Stx1 in human HeLa cells assessed as stimulation of protein synthesis by measuring increase in [14C]-leucine incorporation incubated with cells for 1 hr prior to Stx1 addition and further incubated for 1 to 24 hrs and subseq	[PMID: 32648758]
Bel-7402	IC₅₀	0.17 3 Compound: 1; BFA	Antiproliferative activity against human Bel-7402 cells measured after 72 hrs by MTT assay Antiproliferative activity against human Bel-7402 cells measured after 72 hrs by MTT assay	[PMID: 35849940]
DU-145	GI₅₀	0.13 3 Compound: 1	Antiproliferative activity against human prostate DU-145 cancer cell line Antiproliferative activity against human prostate DU-145 cancer cell line	[PMID: 11689077]
HepG2	IC₅₀	0.08 3 Compound: BFA	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 36089748]
Bel7402/5-FU	IC₅₀	0.82 3 Compound: BFA; 1	Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by MTT assay	[PMID: 29524728]
DU-145	GI₅₀	0.13 3 Compound: 1	Cytotoxicity against prostate DU-145 cancer cell cultures. Cytotoxicity against prostate DU-145 cancer cell cultures.	[PMID: 9719586]
HepG2	IC₅₀	0.18 3 Compound: 1; BFA	Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay	[PMID: 35849940]
DU-145	IC₅₀	0.16 3 Compound: BFA	Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
HepG2	IC₅₀	0.35 3 Compound: 1; BFA	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 28494251]
ECa-109 cell line	IC₅₀	0.14 3 Compound: 1; BFA	Antiproliferative activity against human Eca-109 cells measured after 72 hrs by MTT assay Antiproliferative activity against human Eca-109 cells measured after 72 hrs by MTT assay	[PMID: 35849940]
HL-60	IC₅₀	0.025 3 Compound: BFA; 1	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 29524728]
HCT-116	GI₅₀	0.03 3 Compound: 1	Antiproliferative activity against HCT116 cell line Antiproliferative activity against HCT116 cell line	[PMID: 16789745]
HT-29	IC₅₀	0.16 3 Compound: 1; BFA	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 28494251]
L02	IC₅₀	< 0.0004 3 Compound: 1; BFA	Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28494251]
HCT-116	GI₅₀	0.029 3 Compound: 1	Antiproliferative activity against human colon HCT116 cancer cell line Antiproliferative activity against human colon HCT116 cancer cell line	[PMID: 11689077]
DU-145	GI₅₀	0.13 3 Compound: 1	Antiproliferative activity against human prostate DU-145 cancer cell line Antiproliferative activity against human prostate DU-145 cancer cell line	[PMID: 11689077]
DU-145	GI₅₀	0.13 3 Compound: 1	Cytotoxicity against prostate DU-145 cancer cell cultures. Cytotoxicity against prostate DU-145 cancer cell cultures.	[PMID: 9719586]
HCT-116	GI₅₀	0.029 3 Compound: 1	Cytotoxicity against colon HCT116 cancer cell cultures. Cytotoxicity against colon HCT116 cancer cell cultures.	[PMID: 9719586]
L02	IC₅₀	< 0.001 3 Compound: BFA; 1	Antiproliferative activity against human LO2 cells after 72 hrs by MTT assay Antiproliferative activity against human LO2 cells after 72 hrs by MTT assay	[PMID: 29524728]
DU-145	IC₅₀	0.16 3 Compound: BFA	Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
L02	IC₅₀	0.1 3 Compound: 1; BFA	Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay	[PMID: 35849940]
HeLa	EC₅₀	5 3 Compound: Brefeldin A	Inhibition of Escherichia coli Stx1 in human HeLa cells assessed as stimulation of protein synthesis by measuring increase in [14C]-leucine incorporation incubated with cells for 1 hr prior to Stx1 addition and further incubated for 1 to 24 hrs and subseq Inhibition of Escherichia coli Stx1 in human HeLa cells assessed as stimulation of protein synthesis by measuring increase in [14C]-leucine incorporation incubated with cells for 1 hr prior to Stx1 addition and further incubated for 1 to 24 hrs and subseq	[PMID: 32648758]
HCT-116	GI₅₀	0.029 3 Compound: 1	Antiproliferative activity against human colon HCT116 cancer cell line Antiproliferative activity against human colon HCT116 cancer cell line	[PMID: 11689077]
HeLa	IC₅₀	0.044 3 Compound: BFA	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
PANC-1	IC₅₀	0.08 3 Compound: 1; BFA	Antiproliferative activity against human PANC-1 cells measured after 72 hrs by MTT assay Antiproliferative activity against human PANC-1 cells measured after 72 hrs by MTT assay	[PMID: 35849940]
HeLa	IC₅₀	0.07 3 Compound: 1; BFA	Antiproliferative activity against human HeLa cells measured after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells measured after 72 hrs by MTT assay	[PMID: 35849940]
HCT-116	GI₅₀	0.029 3 Compound: 1	Cytotoxicity against colon HCT116 cancer cell cultures. Cytotoxicity against colon HCT116 cancer cell cultures.	[PMID: 9719586]
PC-3	IC₅₀	0.068 3 Compound: BFA; 1	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 29524728]
HepG2	IC₅₀	0.35 3 Compound: 1; BFA	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 28494251]
PC-3	IC₅₀	0.068 3 Compound: 1; BFA	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 28494251]
HCT-116	GI₅₀	0.03 3 Compound: 1	Antiproliferative activity against HCT116 cell line Antiproliferative activity against HCT116 cell line	[PMID: 16789745]
HepG2	IC₅₀	0.12 3 Compound: BFA	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
HepG2	IC₅₀	0.08 3 Compound: BFA	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 36089748]
HL-60	IC₅₀	0.025 3 Compound: BFA; 1	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 29524728]
HepG2	IC₅₀	0.18 3 Compound: 1; BFA	Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay	[PMID: 35849940]
HOP-62	GI₅₀	0.07 3 Compound: 1	Antiproliferative activity against human lung HOP-62 cancer cell line Antiproliferative activity against human lung HOP-62 cancer cell line	[PMID: 11689077]
HOP-62	GI₅₀	0.07 3 Compound: 1	Cytotoxicity against lung HOP-62 cancer cell cultures. Cytotoxicity against lung HOP-62 cancer cell cultures.	[PMID: 9719586]
HL-60	IC₅₀	0.025 3 Compound: BFA; 1	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 29524728]
HT-29	IC₅₀	0.16 3 Compound: 1; BFA	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 28494251]
HOP-62	GI₅₀	0.07 3 Compound: 1	Antiproliferative activity against human lung HOP-62 cancer cell line Antiproliferative activity against human lung HOP-62 cancer cell line	[PMID: 11689077]
HOP-62	GI₅₀	0.07 3 Compound: 1	Cytotoxicity against lung HOP-62 cancer cell cultures. Cytotoxicity against lung HOP-62 cancer cell cultures.	[PMID: 9719586]
HeLa	EC₅₀	5 3 Compound: Brefeldin A	Inhibition of Escherichia coli Stx1 in human HeLa cells assessed as stimulation of protein synthesis by measuring increase in [14C]-leucine incorporation incubated with cells for 1 hr prior to Stx1 addition and further incubated for 1 to 24 hrs and subseq Inhibition of Escherichia coli Stx1 in human HeLa cells assessed as stimulation of protein synthesis by measuring increase in [14C]-leucine incorporation incubated with cells for 1 hr prior to Stx1 addition and further incubated for 1 to 24 hrs and subseq	[PMID: 32648758]
HT-29	IC₅₀	0.16 3 Compound: 1; BFA	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 28494251]
HeLa	IC₅₀	0.044 3 Compound: BFA	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
L02	IC₅₀	0.094 3 Compound: BFA	Antiproliferative activity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
HeLa	IC₅₀	0.07 3 Compound: 1; BFA	Antiproliferative activity against human HeLa cells measured after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells measured after 72 hrs by MTT assay	[PMID: 35849940]
L02	IC₅₀	<0.001 3 Compound: BFA; 1	Antiproliferative activity against human LO2 cells after 72 hrs by MTT assay Antiproliferative activity against human LO2 cells after 72 hrs by MTT assay	[PMID: 29524728]
L02	IC₅₀	0.1 3 Compound: 1; BFA	Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay	[PMID: 35849940]
HepG2	IC₅₀	0.08 3 Compound: BFA	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 36089748]
MCF7	GI₅₀	0.02 3 Compound: 1	Antiproliferative activity against human MCF7 cell line Antiproliferative activity against human MCF7 cell line	[PMID: 16789745]
HepG2	IC₅₀	0.12 3 Compound: BFA	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
MDA-MB-231	IC₅₀	0.054 3 Compound: BFA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
HepG2	IC₅₀	0.18 3 Compound: 1; BFA	Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay	[PMID: 35849940]
HepG2	IC₅₀	0.35 3 Compound: 1; BFA	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 28494251]
MDA-MB-435	GI₅₀	0.041 3 Compound: 1	Antiproliferative activity against human breast MDA-MB-435 cancer cell line Antiproliferative activity against human breast MDA-MB-435 cancer cell line	[PMID: 11689077]
MDA-MB-435	GI₅₀	0.041 3 Compound: 1	Cytotoxicity against breast MDA-MB-435 cancer cell cultures. Cytotoxicity against breast MDA-MB-435 cancer cell cultures.	[PMID: 9719586]
OVCAR-3	GI₅₀	0.032 3 Compound: 1	Antiproliferative activity against human ovarian OVCAR-3 cancer cell line Antiproliferative activity against human ovarian OVCAR-3 cancer cell line	[PMID: 11689077]
L02	IC₅₀	0.094 3 Compound: BFA	Antiproliferative activity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
OVCAR-3	GI₅₀	0.03 3 Compound: 1	Antiproliferative activity against human OVCAR-3 cell line Antiproliferative activity against human OVCAR-3 cell line	[PMID: 16789745]
L02	IC₅₀	0.1 3 Compound: 1; BFA	Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay	[PMID: 35849940]
OVCAR-3	GI₅₀	0.032 3 Compound: 1	Cytotoxicity against ovarian OVCAR-3 cancer cell cultures. Cytotoxicity against ovarian OVCAR-3 cancer cell cultures.	[PMID: 9719586]
L02	IC₅₀	< 0.0004 3 Compound: 1; BFA	Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28494251]
PANC-1	IC₅₀	0.08 3 Compound: 1; BFA	Antiproliferative activity against human PANC-1 cells measured after 72 hrs by MTT assay Antiproliferative activity against human PANC-1 cells measured after 72 hrs by MTT assay	[PMID: 35849940]
L02	IC₅₀	< 0.001 3 Compound: BFA; 1	Antiproliferative activity against human LO2 cells after 72 hrs by MTT assay Antiproliferative activity against human LO2 cells after 72 hrs by MTT assay	[PMID: 29524728]
Panel NCI-60 (60 carcinoma cell lines)	GI₅₀	0.04 3 Compound: 1	Antiproliferative activity against NCI60 cell line Antiproliferative activity against NCI60 cell line	[PMID: 16789745]
PC-3	GI₅₀	0.05 3 Compound: 1	Antiproliferative activity against human PC3 cell line Antiproliferative activity against human PC3 cell line	[PMID: 16789745]
PC-3	IC₅₀	0.068 3 Compound: 1; BFA	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 28494251]
MCF7	GI₅₀	0.02 3 Compound: 1	Antiproliferative activity against human MCF7 cell line Antiproliferative activity against human MCF7 cell line	[PMID: 16789745]
PC-3	IC₅₀	0.068 3 Compound: BFA; 1	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 29524728]
MDA-MB-231	IC₅₀	0.054 3 Compound: BFA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
SF-539	GI₅₀	0.04 3 Compound: 1	Antiproliferative activity against human CNS SF-539 cancer cell line Antiproliferative activity against human CNS SF-539 cancer cell line	[PMID: 11689077]
MDA-MB-435	GI₅₀	0.041 3 Compound: 1	Antiproliferative activity against human breast MDA-MB-435 cancer cell line Antiproliferative activity against human breast MDA-MB-435 cancer cell line	[PMID: 11689077]
SF-539	GI₅₀	0.04 3 Compound: 1	Antiproliferative activity against human SF539 cell line Antiproliferative activity against human SF539 cell line	[PMID: 16789745]
MDA-MB-435	GI₅₀	0.041 3 Compound: 1	Cytotoxicity against breast MDA-MB-435 cancer cell cultures. Cytotoxicity against breast MDA-MB-435 cancer cell cultures.	[PMID: 9719586]
SF-539	GI₅₀	0.04 3 Compound: 1	Cytotoxicity against CNS SF-539 cancer cell cultures. Cytotoxicity against CNS SF-539 cancer cell cultures.	[PMID: 9719586]
SN12C	GI₅₀	0.09 3 Compound: 1	Antiproliferative activity against human renal SN12C cancer cell line Antiproliferative activity against human renal SN12C cancer cell line	[PMID: 11689077]
SN12C	GI₅₀	0.09 3 Compound: 1	Antiproliferative activity against human SN12C cell line Antiproliferative activity against human SN12C cell line	[PMID: 16789745]
OVCAR-3	GI₅₀	0.03 3 Compound: 1	Antiproliferative activity against human OVCAR-3 cell line Antiproliferative activity against human OVCAR-3 cell line	[PMID: 16789745]
OVCAR-3	GI₅₀	0.032 3 Compound: 1	Antiproliferative activity against human ovarian OVCAR-3 cancer cell line Antiproliferative activity against human ovarian OVCAR-3 cancer cell line	[PMID: 11689077]
SN12C	GI₅₀	0.09 3 Compound: 1	Cytotoxicity against renal SN12C cancer cell cultures. Cytotoxicity against renal SN12C cancer cell cultures.	[PMID: 9719586]
L02	IC₅₀	<0.4 1 Compound: 1; BFA	Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28494251]
OVCAR-3	GI₅₀	0.032 3 Compound: 1	Cytotoxicity against ovarian OVCAR-3 cancer cell cultures. Cytotoxicity against ovarian OVCAR-3 cancer cell cultures.	[PMID: 9719586]
UACC-62	GI₅₀	0.022 3 Compound: 1	Antiproliferative activity against human melanoma UACC-62 cancer cell line Antiproliferative activity against human melanoma UACC-62 cancer cell line	[PMID: 11689077]
UACC-62	GI₅₀	0.02 3 Compound: 1	Antiproliferative activity against human UACC62 cell line Antiproliferative activity against human UACC62 cell line	[PMID: 16789745]
PANC-1	IC₅₀	0.08 3 Compound: 1; BFA	Antiproliferative activity against human PANC-1 cells measured after 72 hrs by MTT assay Antiproliferative activity against human PANC-1 cells measured after 72 hrs by MTT assay	[PMID: 35849940]
UACC-62	GI₅₀	0.022 3 Compound: 1	Cytotoxicity against melanoma UACC-62 cancer cell cultures. Cytotoxicity against melanoma UACC-62 cancer cell cultures.	[PMID: 9719586]
PC-3	GI₅₀	0.05 3 Compound: 1	Antiproliferative activity against human PC3 cell line Antiproliferative activity against human PC3 cell line	[PMID: 16789745]
PC-3	IC₅₀	0.068 3 Compound: 1; BFA	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 28494251]
PC-3	IC₅₀	0.068 3 Compound: BFA; 1	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 29524728]
Panel NCI-60 (60 carcinoma cell lines)	GI₅₀	0.04 3 Compound: 1	Antiproliferative activity against NCI60 cell line Antiproliferative activity against NCI60 cell line	[PMID: 16789745]
SF-539	GI₅₀	0.04 3 Compound: 1	Antiproliferative activity against human CNS SF-539 cancer cell line Antiproliferative activity against human CNS SF-539 cancer cell line	[PMID: 11689077]
SF-539	GI₅₀	0.04 3 Compound: 1	Antiproliferative activity against human SF539 cell line Antiproliferative activity against human SF539 cell line	[PMID: 16789745]
SF-539	GI₅₀	0.04 3 Compound: 1	Cytotoxicity against CNS SF-539 cancer cell cultures. Cytotoxicity against CNS SF-539 cancer cell cultures.	[PMID: 9719586]
SN12C	GI₅₀	0.09 3 Compound: 1	Antiproliferative activity against human renal SN12C cancer cell line Antiproliferative activity against human renal SN12C cancer cell line	[PMID: 11689077]
SN12C	GI₅₀	0.09 3 Compound: 1	Antiproliferative activity against human SN12C cell line Antiproliferative activity against human SN12C cell line	[PMID: 16789745]
SN12C	GI₅₀	0.09 3 Compound: 1	Cytotoxicity against renal SN12C cancer cell cultures. Cytotoxicity against renal SN12C cancer cell cultures.	[PMID: 9719586]
UACC-62	GI₅₀	0.02 3 Compound: 1	Antiproliferative activity against human UACC62 cell line Antiproliferative activity against human UACC62 cell line	[PMID: 16789745]
UACC-62	GI₅₀	0.022 3 Compound: 1	Antiproliferative activity against human melanoma UACC-62 cancer cell line Antiproliferative activity against human melanoma UACC-62 cancer cell line	[PMID: 11689077]
UACC-62	GI₅₀	0.022 3 Compound: 1	Cytotoxicity against melanoma UACC-62 cancer cell cultures. Cytotoxicity against melanoma UACC-62 cancer cell cultures.	[PMID: 9719586]

In Vitro

Brefeldin A (BFA) treatment for 15 h or 40 h, causes dramatic swelling of the Endoplasmic Reticulum (ER) and shifts its localization to the periphery of normal rat kidney (NRK) cells. Prolonged Brefeldin A treatment results in marked disruption of the MT and actin cytoskeleton^[1]. ADP-ribosylation of BARS is mediated by formation of a conjugate between Brefeldin A and ADPR. BARS shows BAC binding when incubated with the medium from the BFA-treated CD38⁺ HeLa cells^[3]. Brefeldin A induces anchorage-independent cell death in MDA-MB-231 breast cancer cells, inhibits the formation of MDA-MB-231 colonies in 3D and 2D cultures and inhibits the migration and MMP 9 (Matrix Metallopeptidase 9) activity of MDA-MB-231^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

분자량

280.36

화학식

C₁₆H₂₄O₄

CAS No.

20350-15-6

Appearance

Solid

Color

White to off-white

SMILES

O[C@@H]1C[C@]2([H])[C@@](/C=C/CCC[C@H](C)OC(/C=C/[C@H]2O)=O)([H])C1

Structure Classification

Initial Source

Microorganisms

Penicillium

선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

용액&용해도

In Vitro:

DMSO : 100 mg/mL (356.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 11.11 mg/mL (39.63 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.5668 mL	17.8342 mL	35.6684 mL
5 mM	0.7134 mL	3.5668 mL	7.1337 mL
10 mM	0.3567 mL	1.7834 mL	3.5668 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

몰농도 계산기
농도 희석 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.92 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.92 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.92 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 4

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.92 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 5

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.92 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 6

Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.92 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

순도&문서

Purity: 99.82%

Select Batch:

Data Sheet (286 KB) SDS (479 KB)

COA (258 KB) LCMS (99 KB)

Handling Instructions (2659 KB)

References

[1]. Alvarez C, et al. Brefeldin A (BFA) disrupts the organization of the microtubule and the actin cytoskeletons. Eur J Cell Biol. 1999 Jan;78(1):1-14. [Content Brief]

[2]. Tseng CN, et al. Brefeldin A reduces anchorage-independent survival, cancer stem cell potential and migration of MDA-MB-231 human breast cancer cells. Molecules. 2014 Oct 29;19(11):17464-77. [Content Brief]

[3]. Wang J, et al. Erythroleukemia cells acquire an alternative mitophagy capability. Sci Rep. 2016 Apr 19;6:24641. [Content Brief]

[4]. Colanzi A, et al. Molecular mechanism and functional role of brefeldin A-mediated ADP-ribosylation of CtBP1/BARS. Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9794-9. [Content Brief]

[5]. Yu C, et al. Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell. 2015 Feb 5;16(2):142-7. [Content Brief]

[6]. Nozawa N, et al. Subcellular localization of herpes simplex virus type 1 UL51 protein and role of palmitoylation in Golgi apparatus targeting. J Virol. 2003 Mar;77(5):3204-16. [Content Brief]

[7]. Jensen HL, Rygaard J, Norrild B. A time-related study of Brefeldin A effects in HSV-1 infected cultured human fibroblasts. APMIS. 1995;103(7-8):530-539. doi:10.1111/j.1699-0463.1995.tb01402.x [Content Brief]

Cell Assay
^[1]

Cells are grown on glass coverslips, fixed in 3 % paraformaldehyde in PBS (10 min at room temperature) and then washed in PBS. Cells are permeabilized with 0.01 % Triton X-lOO in PBS at room temperature for 7 min. The coverslips are washed (3 times in PBS/0.2 % Tween) incubated in PBS/O.4 % fish skin gelatin/0.2 % Tween (5 min) and in PBS/2.5 % goat serum/0.2 % Tween (5 min.). After blocking, the cells are incubated with primary antibodies for 45 min at 37°C, and then washed with PBS/0.2 % Tween (5 times, 5 min each). The secondary antibodies are added for 30 min at 37°C and then cells are washed as above. Coverslips are mounted on slides in 9: 1 glycerol/PBS with 0.1 % o-phenylenediamine.

MCE 는 독립적으로 이러한 방법들의 정확성을 확인하지 않았습니다. 참고용으로만 봐주십시오.

References

[1]. Alvarez C, et al. Brefeldin A (BFA) disrupts the organization of the microtubule and the actin cytoskeletons. Eur J Cell Biol. 1999 Jan;78(1):1-14. [Content Brief]

[2]. Tseng CN, et al. Brefeldin A reduces anchorage-independent survival, cancer stem cell potential and migration of MDA-MB-231 human breast cancer cells. Molecules. 2014 Oct 29;19(11):17464-77. [Content Brief]

[3]. Wang J, et al. Erythroleukemia cells acquire an alternative mitophagy capability. Sci Rep. 2016 Apr 19;6:24641. [Content Brief]

[4]. Colanzi A, et al. Molecular mechanism and functional role of brefeldin A-mediated ADP-ribosylation of CtBP1/BARS. Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9794-9. [Content Brief]

[5]. Yu C, et al. Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell. 2015 Feb 5;16(2):142-7. [Content Brief]

[6]. Nozawa N, et al. Subcellular localization of herpes simplex virus type 1 UL51 protein and role of palmitoylation in Golgi apparatus targeting. J Virol. 2003 Mar;77(5):3204-16. [Content Brief]

[7]. Jensen HL, Rygaard J, Norrild B. A time-related study of Brefeldin A effects in HSV-1 infected cultured human fibroblasts. APMIS. 1995;103(7-8):530-539. doi:10.1111/j.1699-0463.1995.tb01402.x [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

Ethanol / DMSO	1 mM	3.5668 mL	17.8342 mL	35.6684 mL	89.1711 mL
	5 mM	0.7134 mL	3.5668 mL	7.1337 mL	17.8342 mL
	10 mM	0.3567 mL	1.7834 mL	3.5668 mL	8.9171 mL
	15 mM	0.2378 mL	1.1889 mL	2.3779 mL	5.9447 mL
	20 mM	0.1783 mL	0.8917 mL	1.7834 mL	4.4586 mL
	25 mM	0.1427 mL	0.7134 mL	1.4267 mL	3.5668 mL
	30 mM	0.1189 mL	0.5945 mL	1.1889 mL	2.9724 mL
DMSO	40 mM	0.0892 mL	0.4459 mL	0.8917 mL	2.2293 mL
	50 mM	0.0713 mL	0.3567 mL	0.7134 mL	1.7834 mL
	60 mM	0.0594 mL	0.2972 mL	0.5945 mL	1.4862 mL
	80 mM	0.0446 mL	0.2229 mL	0.4459 mL	1.1146 mL
	100 mM	0.0357 mL	0.1783 mL	0.3567 mL	0.8917 mL

Brefeldin A Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Brefeldin A20350-15-6BFA Cyanein DecumbinAutophagyMitophagyHSVAntibioticBacterialMitochondrial AutophagyHerpes simplex virusInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
상품명			Requested Quantity *
고객명 *			호칭
메일주소 *			전화번호 *
Department			회사명 *
City			도
Country or Region *
비고

상품명			Lot #
고객명 *			메일주소 *
전화번호			Department *
회사명 *			Country or Region *
비고

Name
이메일 *

	Sorry, but the email address you supplied was invalid.

Brefeldin A (Synonyms: BFA; Cyanein; Decumbin)

고객리뷰

Other Forms of Brefeldin A:

Brefeldin A Related Antibodies

153 Publications Citing Use of MCE Brefeldin A

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HSV Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

Biological Activity

Protocol

순도&문서

References

고객리뷰

Brefeldin A Related Antibodies

몰농도 계산기

농도 희석 계산기

Complete Stock Solution Preparation Table

Brefeldin A Related Classifications

Keywords:

최근 본 상품:

고객리뷰

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report